FLOT

Brief title: FLOT
Design: Biweekly fluorouracil, leucovirin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction.
No of patients: 59
Status: Completed

Multicentre, open phase II study with FLOT for patients with metastatic adenocarcinoma of the stomach or esophageal junction. Primary end point was the resonse rate. Secondary end points were toxicities and progression free survival.

LKP:
Prof. Dr. S.E. Al-Batran
Institut für Klinisch-Onkologische Forschung
Krankenhaus Nordwest GmbH
Steinbacher Hohl 2-26
60488 Frankfurt/Main

More information